Clinical pharmacology of antithrombotic drugs in coronary artery disease

Therapeutic Advances in Cardiovascular Disease

Volumn 3, Issue 6, 2009, Pages 465-478

  Fauler, Joachim ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Anticoagulants; Antiplatelet agents; Antiplatelet drugs; Aspirin; Bivalirudin; Clinical pharmacology; Clopidogrel; Dalteparin; Enoxaparin; Fondaparinux; Fractionated heparin; GP IIb IIIa inhibitors; Prasugrel; Unfractionated heparin

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; CYTOCHROME P450 2C19; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; LYSINE ACETYLSALICYLATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; TIROFIBAN; WARFARIN;

ACUTE CORONARY SYNDROME; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BLEEDING; BRAIN HEMORRHAGE; CAUSE OF DEATH; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; HEART DEATH; HEART INFARCTION; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; HYPOKALEMIA; INJECTION SITE PAIN; INSOMNIA; LOADING DRUG DOSE; LOW DRUG DOSE; NAUSEA; NEUTROPENIA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ORAL BLEEDING; OSTEOPOROSIS; PERCUTANEOUS CORONARY INTERVENTION; PHARYNX HEMORRHAGE; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SKIN NECROSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; URINARY TRACT INFECTION; UROGENITAL TRACT DISEASE; URTICARIA;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DRUG RESISTANCE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 75149121016     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944709346517     Document Type: Review

References (71)

1. Anderson, J.L., Adams, C.D., Antman, E.M., Bridges, C.R., Califf, R.M., Casey Jr, D.E. et al. (2007) ACC / AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-St-Elevation Myocardial Infarction: A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: e1-e157.
2. Ang, L. and Mahmud, E. ( 2008) Monitoring oral antiplatelet therapy: is it justified ? Ther Adv Cardiovasc Dis 2: 485-496.
3. Angiolillo, D.J., Bates, E.R. and Bass, T.A. ( 2008a) Clinical profile of prasugrel, a novel thienopyridine. Am Heart J 156: S16-S22
4. Angiolillo, D.J., Suryadevara, S., Capranzano, P. and Bass, T.A. ( 2008b) Prasugrel: A novel platelet ADP P2y12 receptor antagonist. A review on its mechanism of action and clinical development. Expert Opin Pharmacother 9: 2893-2900.
5. Antiplatelet Antithrombotic Trialist's collaboration. (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86.
6. Antman, E.M., Hand, M., Armstrong, P.W., Bates, E.R., Green, L.A., Halasyamani, L.K. et al. (2008) 2007 Focused update of the ACC / AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51: 210-247.
7. Banks, L.M., Lees, B., Macsweeney, J.E. and Stevenson, J.C. ( 1994) Effect of degenerative spinal and aortic calcification on bone density measurements in post-menopausal women: links between osteoporosis and cardiovascular disease? Eur J Clin Invest 24: 813-817.
8. Bennett, C.L., Connors, J.M., Carwile, J.M., Moake, J.L., Bell, W.R., Tarantolo, S.R. et al. (2000) Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 342: 1773-1777.
9. Bergqvist, D. ( 2006) Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery. Vasc Health Risk Manag 2: 365-370.
10. Bhatt, D.L., Scheiman, J., Abraham, N.S., Antman, E.M., Chan, F.K., Furberg, C.D. et al. (2008) ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 52: 1502-1517.
11. Bijsterveld, N.R., Moons, A.H., Boekholdt, S.M., van Aken, B.E., Fennema, H., Peters, R.J. et al. (2002) Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106: 2550-2554.
12. Blann, A.D., Landray, M.J. and Lip, G.Y. ( 2002) ABC of antithrombotic therapy: an overview of antithrombotic therapy. BMJ 325: 762-765.
13. Bowry, A.D., Brookhart, M.A. and Choudhry, N.K. ( 2008) Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol 101: 960-966.
14. Coller, B.S. and Shattil, S.J. ( 2008) The GP IIb / IIIa (Integrin AlphaIIbbeta3) Odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 112: 3011-3025.
15. Collet, J.P., Hulot, J.S., Pena, A., Villard, E., Esteve, J.B., Silvain, J. et al. (2009) Cytochrome P 450 2c19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373: 309-317.
16. Cuisset, T., Frere, C., Quilici, J., Gaborit, B., Bali, L., Poyet, R. et al. (2009) Aspirin noncompliance is the major cause of ‘aspirin resistance’ in patients undergoing coronary stenting. Am Heart J 157: 889-893.
17. Curran, M.P. and Keating, G.M. ( 2005) Eptifibatide: a review of its use in patients with acute coronary syndromes and / or undergoing percutaneous coronary intervention. Drugs 65: 2009-2035.
18. Davi, G. and Patrono, C. ( 2007) Platelet activation and atherothrombosis. N Engl J Med 357: 2482-2494.
19. de Abajo, F.J. and Garcia Rodriguez, L.A. ( 2001) Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 1: 1.
20. Dunn, C.J. and Jarvis, B. ( 2000) Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease. Drugs 60: 203-237.
21. Duvall, W.L. ( 2006) Antithrombotic therapy. Curr Mol Med 6: 603-619.
22. Fareed, J., Hoppensteadt, D., Walenga, J., Iqbal, O., Ma, Q., Jeske, W. et al. (2003) Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice. Clin Pharmacokinet 42: 1043-1057.
23. Fitzgerald, G.A. ( 2003) Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet 361: 542-544.
24. Fraker Jr, T.D., Fihn, S.D., Gibbons, R.J., Abrams, J., Chatterjee, K., Daley, J. et al. (2007) 2007 Chronic Angina Focused Update of the ACC / AHA 2002 Guidelines for the Management of Patients with Chronic Stable Angina: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines Writing Group to Develop the Focused Update of the 2002 Guidelines for the Management of Patients with Chronic Stable Angina. J Am Coll Cardiol 50: 2264-2274.
25. Furie, B. and Furie, B.C. ( 2008) Mechanisms of thrombus formation. N Engl J Med 359: 938-949.
26. Gengo, F.M., Rubin, L., Robson, M., Rainka, M., Gengo, M.F., Mager, D.E. et al. (2008) Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. J Clin Pharmacol 48: 117-122.
27. Gilchrist, I.C., O'Shea, J.C., Kosoglou, T., Jennings, L.K., Lorenz, T.J., Kitt, M.M. et al. (2001) Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 104: 406-411.
28. Gori, A.M., Marcucci, R., Migliorini, A., Valenti, R., Moschi, G., Paniccia, R. et al. (2008) Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 52: 734-739.
29. Gurbel, P.A., Becker, R.C., Mann, K.G., Steinhubl, S.R. and Michelson, A.D. ( 2007) Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50: 1822-1834.
30. Gurbel, P.A. and Tantry, US ( 2006) Aspirin and clopidogrel resistance: consideration and management. J Interv Cardiol 19: 439-448.
31. Hankey, G.J. and Eikelboom, J.W. ( 2006) Aspirin resistance. Lancet 367: 606-617.
32. Hennekens, C.H., Dyken, M.L. and Fuster, V. ( 1997) Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 96: 2751-2753.
33. Hirsh, J., Bauer, K.A., Donati, M.B., Gould, M., Samama, M.M. and Weitz, J.I. ( 2008) Parenteral anticoagulants: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th edition). Chest 133: 141S-159S.
34. Ibbotson, T., Mcgavin, J.K. and Goa, K.L. ( 2003) Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs 63: 1121-1163.
35. Jarvis, B. and Simpson, K. ( 2000) Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 60: 347-377.
36. Johnson, S.G., Rogers, K., Delate, T. and Witt, D.M. ( 2008) Outcomes associated with combined antiplatelet and anticoagulant therapy. Chest 133: 948-954.
37. Juurlink, D.N., Gomes, T., Ko, D.T., Szmitko, P.E., Austin, P.C., Tu, J.V. et al. (2009) A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180: 713-18.
38. Kabbani, S.S., Aggarwal, A., Terrien, E.F., Dibattiste, P.M., Sobel, B.E. and Schneider, D.J. ( 2002) Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 89: 647-650.
39. Kelly, J.P., Kaufman, D.W., Jurgelon, J.M., Sheehan, J., Koff, R.S. and Shapiro, S. ( 1996) Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348: 1413-1416.
40. King 3rd, S.B., Smith Jr, S.C., Hirshfeld Jr, J.W., Jacobs, A.K., Morrison, D.A., Williams, D.O. et al. (2008) 2007 Focused update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51: 172-209.
41. Krasopoulos, G., Brister, S.J., Beattie, W.S. and Buchanan, M.R. ( 2008) Aspirin ‘resistance’ and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336: 195-198.
42. Kwa, A.T. and Rogers, J.H. ( 2008) Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy. J Interv Cardiol 21: 107-117.
43. Lev, E.I., Patel, R.T., Maresh, K.J., Guthikonda, S., Granada, J., Delao, T. et al. (2006) Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47: 27-33.
44. Mahmud, E. and Ang, L. ( 2006) Monitoring antiplatelet therapy during peripheral vascular and coronary interventions. Tech Vasc Interv Radiol 9: 56-63.
45. Mandava, P., Thiagarajan, P. and Kent, T.A. ( 2008) Glycoprotein IIb / IIIa antagonists in acute ischaemic stroke: current status and future directions. Drugs 68: 1019-1028.
46. Mason, P.J., Jacobs, A.K. and Freedman, J.E. ( 2005) Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 46: 986-993.
47. McTavish, D., Faulds, D. and Goa, K.L. ( 1990) Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 40: 238-259.
48. Menozzi, A., Merlini, P.A. and Ardissino, D. ( 2005) Tirofiban in acute coronary syndromes. Expert Rev Cardiovasc Ther 3: 193-206.
49. Moen, M.D., Keating, G.M. and Wellington, K. ( 2005) Bivalirudin: a review of its use in patients undergoing percutaneous coronary intervention. Drugs 65: 1869-1891.
50. Mukherjee, D. and Roffi, M. ( 2007) Current strategies with high-dose tirofiban. Expert Opin Drug Metab Toxicol 3: 275-280.
51. Mukherjee, D., Topol, E.J., Bertrand, M.E., Kristensen, S.D., Herrmann, H.C., Neumann, F.J. et al. (2005) Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and reopro give similar efficacy outcomes at trial 1-year follow-up. Eur Heart J 26: 2524-2528.
52. Patrono, C., Baigent, C., Hirsh, J. and Roth, G. ( 2008) Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133: 199S-233S.
53. Patrono, C., Garcia Rodriguez, L.A., Landolfi, R. and Baigent, C. ( 2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353: 2373-2383.
54. Pollack Jr, C.V. and Goldberg, A.D. ( 2008) The medical management of acute coronary syndromes and potential roles for new antithrombotic agents. J Emerg Med 34: 417-428.
55. Reeder, G.S. ( 1995) Adjunctive therapy in the management of patients with acute myocardial infarction. Mayo Clin Proc 70: 464-468.
56. Saltiel, E. and Ward, A. ( 1987) Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 34: 222-262.
57. Sanchez-Borges, M., Capriles-Hulett, A. and Caballero-Fonseca, F. ( 2002) NSAID-induced urticaria and angioedema: a reappraisal of its clinical management. Am J Clin Dermatol 3: 599-607.
58. Sanderson, S., Emery, J., Baglin, T. and Kinmonth, A.L. ( 2005) Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 142: 370-380.
59. Schneider, D.J., Herrmann, H.C., Lakkis, N., Aguirre, F., Wan, Y., Aggarwal, A. et al. (2002) Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 90: 1421-1423.
60. Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Meneveau, N. et al. (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360: 363-375.
61. Smit, J.J. and van't Hof, A.W. (2007) Does glycoprotein IIb / IIIa resistance exist? Neth Heart J 15: 367-368.
62. Szczeklik, A. and Stevenson, D.D. ( 2003) Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 111: 913-921; quiz 922.
63. Topol, E.J., Moliterno, D.J., Herrmann, H.C., Powers, E.R., Grines, C.L., Cohen, D.J. et al. (2001) Comparison of two platelet glycoprotein IIb / IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344: 1888-1894.
64. Warkentin, T.E., Greinacher, A. and Koster, A. (2009) Heparin-induced thrombocytopenia in patients with ventricular assist devices: are new prevention strategies required? Ann Thorac Surg 87: 1633-1640.
65. Weil, J., Colin-Jones, D., Langman, M., Lawson, D., Logan, R., Murphy, M. et al. (1995) Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310: 827-830.
66. Wienbergen, H. and Zeymer, U. ( 2007) Management of acute coronary syndromes with fondaparinux. Vasc Health Risk Manag 3: 321-329.
67. Wiviott, S.D., Antman, E.M., Winters, K.J., Weerakkody, G., Murphy, S.A., Behounek, B.D. et al. (2005) Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 Antagonist, with Clopidogrel in Percutaneous Coronary Intervention: Results of the joint utilization of medications to block platelets optimally (jumbo)-TIMI 26 trial. Circulation 111: 3366-3373.
68. Wiviott, S.D., Braunwald, E., McCabe, C.H., Montalescot, G., Ruzyllo, W., Gottlieb, S. et al. (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-2015.
69. Yeomans, N.D., Lanas, A.I., Talley, N.J., Thomson, A.B., Daneshjoo, R., Eriksson, B. et al. (2005) Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 22: 795-801.
70. Yusuf, S., Mehta, S.R., Chrolavicius, S., Afzal, R., Pogue, J., Granger, C.B. et al. (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the Oasis-6 randomized trial. JAMA 295: 1519-1530.
71. Zeidan, A.M., Kouides, P.A., Tara, M.A. and Fricke, W.A. ( 2007) Platelet function testing: state of the art. Expert Rev Cardiovasc Ther 5: 955-967.